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Abstract
Aims/hypothesis This meta-analysis assessed the pooled
effect of each genetic variant reproducibly associated with
diabetic nephropathy.
Methods PubMed, EMBASE and Web of Science were
searched for articles assessing the association between
genes and diabetic nephropathy. All genetic variants
statistically associated with diabetic nephropathy in an
initial study, then independently reproduced in at least one
additional study, were selected. Subsequently, all studies
assessing these variants were included. The association
between these variants and diabetic nephropathy (defined as
macroalbuminuria/proteinuria or end-stage renal disease
[ESRD]) was calculated at the allele level and the main
measure of effect was a pooled odds ratio. Pre-specified
subgroup analyses were performed, stratifying for type 1/
type 2 diabetes mellitus, proteinuria/ESRD and ethnic
group.
Results The literature search yielded 3,455 citations, of
which 671 were genetic association studies investigating
diabetic nephropathy. We identified 34 replicated genetic
variants. Of these, 21 remained significantly associated
with diabetic nephropathy in a random-effects meta-
analysis. These variants were in or near the following
genes: ACE, AKR1B1 (two variants), APOC1, APOE, EPO,
NOS3 (two variants), HSPG2, VEGFA, FRMD3 (two
variants), CARS (two variants), UNC13B, CPVL and
CHN2, and GREM1, plus four variants not near genes.
The odds ratios of associated genetic variants ranged from
0.48 to 1.70. Additional variants were detected in subgroup
analyses: ELMO1 (Asians), CCR5 (Asians) and CNDP1
(type 2 diabetes).
Conclusions/interpretation This meta-analysis found 24
genetic variants associated with diabetic nephropathy. The
relative contribution and relevance of the identified genes in
the pathogenesis of diabetic nephropathy should be the
focus of future studies.
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Diabetes mellitus has rapidly increased to epidemic
proportions over the past few decades. The number of
patients with diabetes mellitus worldwide was estimated at
173millionin2002andispredictedtoincreaseto350million
cases by 2030 [1]. Diabetes mellitus is associated with
severe complications including nephropathy, neuropathy,
retinopathy and accelerated cardiovascular disease.
Diabetic nephropathy is the leading cause of end-stage
renal disease (ESRD) in developed countries [1]. Although
glycaemic control inversely relates to the degree of
microvascular complications including diabetic nephropa-
thy [2], some patients appear to be at increased risk. The
majority of patients with type 1 diabetes mellitus will either
develop diabetic nephropathy within the first 15 years after
diagnosis or will remain relatively protected thereafter [3].
Differential disease risk in diabetic nephropathy may be
partly attributable to genetic susceptibility. Evidence for a
genetic component to diabetic nephropathy comes from
family studies displaying familial aggregation of diabetic
nephropathy both in type 1 and in type 2 diabetes mellitus
[4–6], as well as differences in the prevalence of diabetic
nephropathy between ethnic groups [7, 8].
The literature involving genetic associations in complex
disease has been plagued by inconsistencies [9]. Small
sample sizes and false positive results were often respon-
sible for lack of reproducibility [10]. In addition, the prior
probabilities of genetic associations are low. Therefore, the
number of false positive associations generated by chance
alone is high, particularly when low prior probabilities were
not accounted for in the statistical analyses [11]. Incorrect
phenotyping may also lead to spurious results. Thus
independent replication of association remains essential in
order to avoid false positive associations. The aim of this
meta-analysis was to assess the pooled effect of genetic
variants that have reproducibly been associated with
diabetic nephropathy.
Methods
Eligibility criteria We searched for studies comparing
genetic variants in diabetes mellitus patients with diabetic
nephropathy, relative to diabetes mellitus patients without
diabetic nephropathy. We limited our analyses to studies
investigating established and advanced diabetic nephropa-
thy. To be included, all cases in the report had to have
diabetes mellitus with macroalbuminuria and/or overt
proteinuria, ESRD attributed to diabetic nephropathy or
biopsy-proven diabetic nephropathy. In addition, diabetic
control participants had to have either: (1) normoalbumi-
nuria; (2) normoalbuminuria or microalbuminuria after
>15 years diabetes mellitus duration (microalbuminuria
developing after >15 years diabetes mellitus duration is a
poor predictor of diabetic nephropathy [3]); (3) stable
kidney function (serum creatinine <106.1 μmol/l) after
>15 years of diabetes mellitus, irrespective of albuminuria.
Studies were excluded when the control group consisted
of non-diabetic participants, since in that case genetic
associations ascribed to diabetic nephropathy could have
been due to diabetes mellitus. Follow-up and case–control
studies were both eligible for inclusion in the meta-analysis.
Literature search and data collection A search strategy was
devised in collaboration with a trained librarian. The
following databases were searched: PubMed (1949 to April
2010), EMBASE (OVID-version, 1980 to April 2010) and
Web of Science (1945 to April 2010). The search strategy
consisted of multiple queries combining: ‘Diabetic Ne-
phropathy’ and ‘Genes’ or ‘Polymorphisms’. For these two
concepts, all relevant keyword variations were used. In
addition, the names of specific genes and polymorphisms
were combined with the topic ‘Diabetic Nephropathy’. This
search strategy was optimised for every database consulted,
taking into account differences in the various controlled
vocabularies and different database-specific technical var-
iations. The search was performed in April 2010. To ensure
maximum sensitivity, limits or filters were not placed on the
searches. Language restrictions were not included in the
initial search. References of other narrative and systematic
reviews were also checked for relevant articles. The search
strategy was updated if a reference was missing. The
process was performed three times to ensure that no
references were omitted.
Two authors (A. L. Mooyaart and E. J. J. Valk) of this
study independently reviewed the titles and abstracts of the
citations to identify genetic association studies. Genetic
association studies were screened for whether the study
contained a positive or a negative association between the
genetic variant and diabetic nephropathy (association
defined as significant at p<0.05). When a genetic variant
was found to be associated with established or advanced
diabetic nephropathy (either at the allelic or genotypic
level, including the recessive and dominant model) in two
independent studies, that variant was considered to be a
reproduced genetic variant. For these replicated variants, all
other genetic studies were identified to estimate the effect of
the variant on diabetic nephropathy, irrespective of p values.
Data extraction and analysis The main outcome of the
meta-analysis was the pooled odds ratio for the association
between reproduced genetic variants and diabetic nephropa-
thy. Odds ratios were calculated at allele level and not at
genotype level. Of the reproduced genes, allele frequencies
were extracted from studies. For single nucleotide poly-
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compared between diabetic nephropathy cases and non-
nephropathy diabetic controls. For other genetic variants such
as microsatellites, we compared the allele between cases and
controls, as used in the literature and other meta-analyses
[12, 13]. The random-effects model was performed by
default. Heterogeneity within the studies was estimated by
the I
2, which is the percentage of the total variation across
studies that is due to heterogeneity rather than chance. An
I
2 of 25%, 50% and 75% was considered low, moderate and
high, respectively [14]. Pre-specified stratified analyses were
performed to explain heterogeneity or investigate whether
the reported association was present in a subgroup. Stratified
analysis was performed for diabetes mellitus type (type 1 or
type 2), diabetic nephropathy stage (macroalbuminuria and/
or overt proteinuria, established diabetic nephropathy and
ESRD [advanced diabetic nephropathy]) [15] and ethnicity
(European vs Asian origin). The subgroup analysis was only
included in this study if the association between the genetic
variant and diabetic nephropathy was reproduced in that
subgroup. We tested for publication bias using the Begg and
Egger tests and provided funnel plots of all genetic variants
which were reproducibly associated with diabetic nephrop-
athy. It should, however, be noted that funnel plot
asymmetry can have other causes than publication bias
[16]. Furthermore, the effect of ethnicity was assessed if
there were sufficient data by metaregression. Most analyses
were performed in Review Manager (RevMan) version 5.0
(The Nordic Cochrane Centre, Copenhagen, Denmark; The
Cochrane Collaboration, 2008), except for the analysis of
publication bias and metaregression, which was performed
in STATA 10.0 (StataCorp, College Station, TX, USA).
Results
Initial search and results The initial literature search
yielded 3,455 citations, 671 of which were genetic
association studies investigating diabetic nephropathy in
humans (Fig. 1). In these studies, we identified 34
reproduced genetic variants in 24 genes associated with
diabetic nephropathy. Data on at least one of these 34
variants were found in 132 articles, representing 153
studies. Only three follow-up studies were included. All
other studies were case–control studies. The maximum
number of studies in an article was five. References of all
articles and details of these studies are shown in the
Electronic supplementary material (ESM) Tables 1 and 2.
The 132 articles were published between 1994 and 2010.
The number of cases included in these articles ranged from
4 to 1,572, and in a study from 4 to 656 cases. Of the 34
reproduced genetic variants, 21 genetic variants in or near
16 genes were significantly associated with diabetic
nephropathy after random-effects meta-analysis (Fig. 2a).
An overview of the pooled odds ratios of all reproduced
variants in relation to diabetic nephropathy is shown in
Fig. 2a, b. The odds ratios of the significant associations
with diabetic nephropathy ranged between 0.48 and 0.78
for protective effects, and 1.12 to 1.70 for risk effects.
Figure 3 contains an overview of the pooled odds ratios of
all reproduced variants in relation to diabetic nephropathy
among subgroups. Three reproduced variants were not
significantly associated with diabetic nephropathy in the
whole population after meta-analyses, but were associated
in one subgroup: rs1799987 of CCR5 and rs741301 of
ELMO1 in the Asian subgroup, and D18S880 of the
CNDP1 gene in patients with type 2 diabetes mellitus.
Details of analyses of all assessed genetic variants are
provided in Table 1. Forest plots of all individual genetic
variants and funnel plots for publication bias, as well as
results of meta-regression for ethnicity are shown in the
ESM (ESM Figs 1–36). If the meta-analysis revealed a
positive association between a given genetic variant and
diabetic nephropathy, and more than ten studies investigat-
ing that variant in relation to diabetic nephropathy were
available, a meta-regression was performed. Only three
genetic variants fitted the above-mentioned criteria (ACE
rs179975, AKRB1 CA repeat Z−2, APOE E2/3/4). In these
variants, metaregression showed that ethnicity did not
explain the heterogeneity (ESM Figs 1–36).
Genetic variants involved in the renin–angiotensin sys-
tem A variant in ACE, rs179975, was the most studied
polymorphism in diabetic nephropathy, with 42 studies
resulting in a pooled odds ratio of 1.24 (95% CI 1.12–1.37).
The association between the deletion of the rs179975
polymorphism and diabetic nephropathy was reproduced
in all subgroups. In the meta-analysis, the rs179975
polymorphism was associated with diabetic nephropathy
in type 1 diabetes mellitus (OR 1.13 [95% CI 1.04–1.23]),
type 2 diabetes mellitus (OR 1.33 [95% CI 1.16–1.52]),
ESRD (OR 1.39 [95% CI 1.21–1.60]), proteinuria (OR 1.20
[95% CI 1.07–1.36]) and in the Asian subgroup (OR 1.28
[95% CI 1.10–1.49]), but not in Europeans. Other variants
in the renin–angiotensin system that were also widely
studied and reproduced, such as the rs699 variant of AGT
with 21 studies and the rs5186 polymorphism of AGTR1
with 15 studies, were not associated with diabetic nephrop-
athy in the meta-analysis.
Genetic variants involved in the polyol pathway The CA
repeat and rs759853 in AKR1B1 were studied in 19 and 9
studies, respectively. The CA repeat has a Z−2 allele
thought to lead to an increased risk of diabetic nephropathy
and a Z+2 allele thought to have a protective effect. The
Z+2 allele and Z−2 allele were both reproducibly associated
546 Diabetologia (2011) 54:544–553with diabetic nephropathy, but only the Z−2 allele remained
associated in a combined meta-analysis with a pooled odds
ratio of 1.12 (95% CI 1.02–1.24). Although reproducibly
associated with diabetic nephropathy in ‘type 1 diabetes
mellitus’ and ‘European’ subgroups, Z−2 was not associat-
ed with diabetic nephropathy in the meta-analysis in these
subgroups. The Z+2 allele was associated with diabetic
nephropathy in the ‘type 1 diabetes mellitus’ and ‘Europe-
an’ subgroups (OR 0.79 [95% CI 0.68–0.92] and OR 0.81
[95% CI 0.66–0.99], respectively). The T allele in SNP
rs759853 was associated with risk of diabetic nephropathy
in the meta-analysis (OR 1.40 [95% CI 1.13–1.74]) and in
the subgroups ‘diabetic nephropathy due to type 1 diabetes
mellitus’ and ‘Europeans’ (OR 1.58 [95% CI 1.01–2.46]
and OR 1.45 [95% CI 1.07–1.97], respectively).
Genetic variants involved in lipid metabolism Two variants
in genes each coding for two different apolipoproteins are
reproducibly associated with diabetic nephropathy and
remained associated with diabetic nephropathy in the
meta-analysis: E2, E3, E4 polymorphism of APOE and
rs4420638 near APOC1. The E2 allele is thought to lead to
an increased risk of diabetic nephropathy and the E4 allele
is thought to have a protective effect. Both the E2 and the
E4 allele were associated with diabetic nephropathy in the
meta-analysis (OR 1.70 [95% CI 1.12–2.58] and OR 0.78
[95% CI 0.62–0.98] respectively). The E2 allele was also
reproducibly associated with diabetic nephropathy in the
subgroups ‘type 2 diabetes mellitus’, ‘Asians’ and ‘Euro-
pean/type 1 diabetes mellitus’ (all studies investigating
Europeans had type 1 diabetes mellitus and vice versa), but
only associated with diabetic nephropathy in the meta-
analysis in the ‘type 2 diabetes mellitus’ and ‘Asian’
subgroups (OR 2.21 [95% CI 1.22–4.00] and OR 2.35
[95% CI 1.29–4.30], respectively). rs4420638 near the
APOC1 gene was studied in two studies and was associated
with diabetic nephropathy in the meta-analysis (OR 1.54
[95% CI 1.29–1.83]). Both studies contained type 1
diabetic nephropathy patients of European descent.
Genetic variants involved in inflammatory cytokines and
angiogenesis rs1799987 of the CCR5 (an inflammatory
cytokine) gene was only associated with diabetic nephrop-
athy in the Asian subgroup (OR 0.58 [95% CI 0.43–0.76])
consisting of four studies (n=1,534), but not in the total
group consisting of nine studies (n=5,527). For the total
group, funnel plot asymmetry was indicated by a significant
Begg test.
Two genes involved in angiogenesis, VEGFA and EPO,
each had a variant that was reproducibly associated with
diabetic nephropathy. rs833061 of VEGFA was associated
with diabetic nephropathy in the meta-analysis in two
studies (n=543) containing only type 1 diabetes mellitus
patients of European origin (OR 0.48 [95% CI 0.37–0.61]).
Excluded: not established diabetic 
nephropathy vs diabetic controls, only 
cases/progression, data not extractable, 
pharmacogenetics or duplicates (n=123)
Articles involving genetic variants in humans with 
diabetic nephropathy (n=671)
Excluded: genes in established or 
advanced diabetic nephropathy of which 
no replication study was published and 
family studies (n=416)
Overall result of database searches (n=3,445)
Articles investigating reproduced genes (n=255)
Excluded: reviews, in vitro and vivo studies, 
investigating other kidney disease, 
cardiovascular disease, etc. (n=2,774)
Included for meta-analysis (n=132 articles, n=153    
studies: 34 reproduced genetic variants in 24 genes) 
Fig. 1 Flowchart showing how
studies were selected for
meta-analysis
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athy (OR 0.67 [95% CI 0.60–0.76]) in three studies
(n=2,773), also in the subgroup with type 1 diabetes
mellitus patients (OR 0.67 [95% CI 0.58–0.76]).
Genetic variants involved in oxidative stress Five genetic
variants in four genes thought to be related to oxidative
stress were reproducibly associated with diabetic nephrop-
athy. The 1/2 polymorphism of HP and rs1801282 of
PPARG were not associated with diabetic nephropathy in
the meta-analysis. For PPARG, funnel plot asymmetry was
observed (p=0.024) suggesting publication bias. The
rs3138808 and the rs2070744 variants of NOS3 were
associated with diabetic nephropathy in the meta-analysis
(OR 1.31 [95% CI 1.02–1.67] and OR 1.39 [95% CI 1.09–
1.78] respectively). The 5L allele of CNDP1 was associated
with diabetic nephropathy only in the ‘type 2 diabetes
mellitus’ subgroup (OR 0.77 [95% CI 0.61–0.97]).
Genetic variants in other pathways rs17300539 of ADI-
POQ, which is believed to mitigate vascular damage, was not
associated with diabetic nephropathy in the meta-analysis.
rs841853 of GLUT1 (also known as SLC2A1), coding for a
glucose transporter, did not show an association with
diabetic nephropathy in eight studies (OR 1.10 [95% CI
0.89–1.35]). rs1129456 of GREM1, which is involved in cell
growth and differentiation, was associated with diabetic
nephropathy (OR 1.53 [95% CI 1.25–1.89]) in two studies
(n=1799). rs3767140 of HSPG2, which is involved in
maintenance of glomerular basement membrane electrostatic
charge, was also associated with diabetic nephropathy in
the meta-analysis (OR 0.72 [95% CI 0.59–0.87]), and
Fig. 3 Genetic variants reproducibly associated with diabetic ne-
phropathy in a subgroup. a All genetic variants in or near a gene that
were reproduced in an independent study and significantly associated
with diabetic nephropathy after meta-analysis in a subgroup. b All
genetic variants in or near a gene that were reproduced in an
independent study, but were not significantly associated with diabetic
nephropathy after meta-analysis in a subgroup. Parentheses (y-axis
labelling) contain the allele used in the comparison. The subgroup in
which the genetic variant was reproducibly associated with diabetic
nephropathy is shown in y-axis label as follows: Asian, T2D (type 2
diabetes), ESRD, T1D (type 1 diabetes), Eur (European), Prot.
(proteinuria)
Fig. 2 Genetic variants reproducibly associated with diabetic ne-
phropathy. a All genetic variants in or near a gene that were
reproduced in an independent study and significantly associated with
diabetic nephropathy after meta-analysis. b All genetic variants in or
near a gene that were reproduced in an independent study, but were
not significantly associated with diabetic nephropathy after meta-
analysis. Parentheses (y-axis labelling) contain the allele used in the
comparison
548 Diabetologia (2011) 54:544–553Table 1 Details of reproduced variants after meta-analysis, including subgroups
Variants
per gene
Minor allele Total/subgroup Studies (n) Cases (n) Controls (n) OR (95%CI) I
2 (%) p value
a
ACE
rs179975 Deletion Total 42 5,721 7,798 1.24 (1.12–1.37) 66 0.061
Type 1 diabetes 14 2,215 2,685 1.13 (1.04–1.23) 44 –
Type 2 diabetes 28 3,506 5,113 1.33 (1.16–1.52) 71 –
ESRD 10 1,405 1,367 1.39 (1.21–1.6) 29 –
Proteinuria 30 4,071 5,593 1.20 (1.07-1.36) 67 –
European 17 2,660 3,221 1.10 (0.99-1.22) 38 –
Asian 19 2,465 3,397 1.28 (1.10–1.56) 65 –
ACACB
rs2268388 T Total 5 1,007 900 0.83 (0.62–1.11) 77 0.624
ADIPOQ
rs17300539 A Total 3 1,104 1,138 1.37 (0.93–2.03) 67 0.117
AGT
rs699 C Total 21 4,117 4,800 1.10 (0.96–1.25) 71 0.85
Type 2 diabetes 10 1,966 2,309 1.11 (0.85–1.45) 83 –
Asian 8 1,717 1,933 1.10 (0.78–1.55) 87 –
AGTR1
rs5186 C Total 15 3,220 3,501 0.99 (0.91–1.08) 40 0.102
European 10 1,564 2,038 1.06 (0.94–1.19) 36 –
Type 1 diabetes 9 1,525 1,920 1.04 (0.92–1.17) 30 –
AKR1B1
CA repeat Z−2 Total 19 2,237 3,017 1.12 (1.02–1.24) 11 0.807
Type 1 diabetes 10 1,380 1,308 1.12 (1.00–1.25) 16 –
European 14 1,654 1,854 1.08 (0.95–1.21) 18 –
Z+2 Total 17 1,894 2,005 0.83 (0.66–1.03) 59 0.805
Type 1 diabetes 10 1,380 1,308 0.79 (0.68–0.92) 60 –
European 11 1,513 1,557 0.81 (0.66–0.99) 40 –
rs759853 T Total 9 1,243 1,933 1.40 (1.13–1.74) 67 0.144
Type 1 diabetes 4 636 537 1.58 (1.01–2.46) 84 –
European 6 854 913 1.45 (1.07–1.97) 75 –
APOC1
rs4420638 G Total 2 857 935 1.54 (1.29–1.83) 0 0.317
APOE
E2, E3, E4 E2 Total 11 1,257 1,555 1.70 (1.12–2.58) 68 0.186
Type 2 diabetes 5 368 751 2.21 (1.22–4.00) 42 –
Asian 4 312 722 2.35 (1.29–4.30) 48 –
European, type 1 diabetes 6 889 803 1.48 (0.84–2.58) 77 –
E4 Total 11 1,257 1,555 0.78 (0.62–0.98) 40 0.186
CARS
rs451041 A Total 3 1,052 2,057 1.37 (1.21–1.54) 0 0.117
rs739401 C Total 2 820 885 1.32 (1.15–1.51) 0 0.317
CCR5
rs1799987 G Total 9 2,562 2,965 0.81 (0.66–1.00) 85 0.012
Asian 4 627 907 0.58 (0.43–0.76) 69 –
CNDP1
D18S880 5L Total 7 2,603 3,136 0.92 (0.82–1.01) 34 0.176
Type 2 diabetes 2 344 329 0.77 (0.61–0.97) 0 –
Diabetologia (2011) 54:544–553 549additionally with diabetic nephropathy in Europeans
with type 1 diabetes mellitus (OR 0.64 [95% CI 0.49–
0.84]). rs13293564 of UNC13B, thought to be involved in
apoptosis, was associated with diabetic nephropathy in
four studies (OR 1.23 [95% CI 1.11–1.35]).
Genetic variants identified by genome-wide association
studies Of the 14 genetic variants found to be reproducibly
associated with diabetic nephropathy from genome-wide
association studies (GWAS), ten remained associated in the
meta-analysis. rs2268388 of ACACB, rs11993333 of PVT1,
Table 1 (continued)
Variants
per gene
Minor allele Total/subgroup Studies (n) Cases (n) Controls (n) OR (95%CI) I
2 (%) p value
a
CPVL and CHN2
rs39059 G Total 2 820 885 0.74 (0.64–0.85) 0 0.317
rs39075 A Total 3 1,052 2,057 0.84 (0.62–1.14) 84 0.602
ELMO1
rs741301 G Total 3 1,366 1,219 1.31 (0.82–2.08) 91 0.602
Asian 2 546 334 1.58 (1.28–1.94) 0 –
EPO
rs1617640 T Total 3 1,618 954 0.67 (0.60–0.76) 0 0.117
Type 1 diabetes 2 1,244 715 0.67 (0.58–0.76) 0 –
FRMD3
rs1888747 C Total 3 1,052 2,057 0.74 (0.65–0.83) 0 0.602
rs10868025 A Total 3 1,052 2,057 0.72 (0.64–0.81) 11 0.117
GLUT1
rs841853 T Total 7 867 1,035 1.10 (0.89–1.35) 53 0.881
GREM1
rs1129456 T Total 2 859 940 1.53 (1.25–1.89) 0 0.317
HP
Hp 1/2 Hp 1 Total 8 718 1,056 0.81 (0.60–1.08) 62 0.322
HSPG2
rs3767140 G Total 4 732 381 0.72 (0.59–0.87) 0 0.384
European, type 1 diabetes 2 417 240 0.64 (0.49–0.84) 0 –
NOS3
rs2070744 C Total 2 273 450 1.39 (1.09–1.78) 0 0.216
rs3138808 a-deletion 393 bp Total 8 1,250 1,368 1.31 (1.02–1.67) 53 0.317
European type 1 diabetes 3 679 657 1.45 (0.97–2.17) 69 –
PPARG
rs1801282 G Total 7 2,468 2,394 0.84 (0.65–1.10) 78 0.024
PVT1
rs11993333 T Total 2 628 661 0.65 (0.39–1.10) 80 0.317
UNC13B
rs13293564 T Total 4 1,572 1,910 1.23 (1.11–1.35) 0 1.00
VEGFA
rs833061 C Total 2 242 301 0.48 (0.37–0.61) 0 0.317
No gene
rs1041466 G Total 3 1,052 2,057 1.38 (1.21–1.58) 0 0.602
rs1411766 A Total 3 1,052 2,057 1.36 (1.20–1.54) 0 0.117
rs7989848 A Total 3 1,052 2,057 1.32 (1.16–1.51) 0 0.117
rs9521445 A Total 2 820 885 1.35 (1.18–1.55) 0 0.317
rs6492208 C Total 3 1,052 2,057 0.85 (0.67–1.06) 0 0.117
aBegg test for funnel plot asymmetry, which is suggestive of publication bias
550 Diabetologia (2011) 54:544–553rs39075 near CPVL and CHN2, and rs6492208 (not near a
gene) were not associated with diabetic nephropathy in the
meta-analysis. Another variant near ‘CPVL and CHN2’,
rs39059, was associated with diabetic nephropathy in two
studies (n=1,705; OR 0.74 [95% CI 0.64–0.85]). rs741301
of ELMO1 was associated with diabetic nephropathy in
Asians with type 2 diabetic nephropathy (OR 1.58 [95% CI
1.28–1.94]), but not in combination with a third study of
European type 1 diabetes mellitus patients. rs451041 and
rs739401 of CARS were associated with diabetic nephrop-
athy in the meta-analysis (OR 1.37 [95% CI 1.21–1.54] and
OR 1.32 [95% CI 1.15–1.51] respectively).
rs1888747 and rs10868025 of FRMD3 were associated
with diabetic nephropathy (OR 0.74 [95% CI 0.65–0.83]
and OR 0.72 [95% CI 0.64–0.81] respectively). Another
four variants, rs1041466, rs1411766, rs7989848 and
rs9521445, which do not lie near a known gene, were
associated with diabetic nephropathy in the meta-analysis
(OR 1.38 [95% CI 1.21–1.58], OR 1.36 [95% CI 1.20–
1.54], OR 1.32 [95% CI 1.16–1.51] and OR 1.35 [95% CI
1.18–1.55] respectively). The variants in CARS, FRMD3,
CPVL and CHN2, and the five variants not near genes were
only investigated in European participants with type 1
diabetes mellitus.
Discussion
In this meta-analysis, 21 genetic variants were associated
with advanced diabetic nephropathy and three additional
variants were associated within specific subgroups. Meta-
analysis of several individual genetic variants in relation to
diabetic nephropathy has been performed previously, but
this is the first complete overview assessing for all genetic
variants that are reproducibly associated with the presence
of diabetic nephropathy. This information could lead to
improved insight into underlying pathogenetic mechanisms.
Variants in or near ACE, AKR1B1 (two variants), APOC1,
APOE, EPO, NOS3 (two variants), HSPG2, VEGFA,
FRMD3 (two variants), CARS (two variants), CPVL and
CHN2, UNC13B and GREM1, as well as four variants not
near known genes, were associated with diabetic nephrop-
athy. ELMO1, CCR5 and CNDP1 were associated with
diabetic nephropathy in a subgroup (‘Asians’ and ‘type 2
diabetes mellitus’ respectively). These results support a role
for the following in the pathogenesis of diabetic nephrop-
athy: renin–angiotensin system, polyol pathway, oxidative
stress, inflammation, angiogenesis, glomerular filtration
barrier defects, apoptosis, and cell growth and differentia-
tion. Functional studies remain to be performed to establish
the precise roles of these variants and pathways. Genetic
variants initially identified using a genome-wide association
approach in and near FRMD3, CARS, ELMO1, and CPVL
and CHN2 were detected. The exact role of these genetic
variants in relation to diabetic nephropathy requires further
elucidation; many of these variants identified in GWAS will
not prove to be causal.
Our analysis has some limitations. Publication bias is a
concern in all meta-analyses. For this study, only published
data in journals were used, discarding data published in
congresses only. Negative studies are less likely to be
published, potentially leading to an overestimation of
effects. Moreover, non-significant genetic associations
might have been underreported in published articles.
Therefore, the effect estimates of the present study should
be interpreted with caution, especially in cases where
associations were based on small numbers of studies and/
or small sample numbers. For example, the rs833061
variant in the VEGFA gene shows the strongest protective
effect, but was investigated in two studies of moderate size.
In these cases, additional studies are necessary to establish
true effect sizes. It should also be acknowledged that by
selecting only genetic variants that were associated with
diabetic nephropathy and for which independent replication
was available, genetic variants with smaller effect sizes may
have been missed, an effect that may have proven
significant using pooled analyses. By selecting only those
genetic variants reproducibly associated with diabetic
nephropathy, we have tried to reduce the chances of
describing false positive associations.
The studies included in the present analysis showed
heterogeneity with respect to ethnicity, study design and
phenotypes. For some of the analysis, the clinical
heterogeneity was accompanied by statistical heteroge-
neity with an I
2 s t a t i s t i co fu pt o9 1 % .H o w e v e r ,t h e r ei s
no fully accepted statistical measure that precisely deter-
mines clinical heterogeneity [16]. To account for potential
heterogeneity, random effects models were performed by
default. These models assume that different studies have
different true effects. To explore potential heterogeneity
due to differences in ethnicity, a meta-regression was
performed.
A study worth mentioning, which appeared after our
inclusion date, is a paper by Maeda et al. [17], in which the
authors investigated the variants found in the genome-wide
association scan of the Genetics of Kidneys in Diabetes and
Diabetes Control and Complications Trial studies [18]i n
four studies, of which three meet our criteria. We combined
the data of Maeda et al. with results of the Genetics of
Kidneys in Diabetes and Diabetes Control and Complica-
tions Trial studies. We found that only the rs451041 of
CARS, and rs1041466, rs9521455 and rs1411766, which
Diabetologia (2011) 54:544–553 551are not near a gene, were associated with diabetic
nephropathy. In contrast to the Genetics of Kidneys in
Diabetes and Diabetes Control and Complications Trial
studies, which investigated Europeans with type 1 diabetes,
Maeda et al. investigated diabetic nephropathy in type 2
diabetes in an Asian population. Therefore, the lack of
association with diabetic nephropathy of the other variants
could be explained by this difference.
The identification of diabetic nephropathy susceptibility
variants can lead to novel biological insights and improved
measures of individual aetiological processes, as indicated
previously [19]. Individual aetiological processes (person-
alised medicine) could allow preventive and therapeutic
interventions in complex disease to be tailored to individ-
uals on the basis of their genetic profiles. From prediction
studies with genetic variants for type 2 diabetes mellitus, it
has been shown that 20 established genetic variants in type
2 diabetes mellitus have an AUC of 0.54 (0.5 means no
predictive value, 1.0 is perfect prediction), in contrast to the
Framingham offspring and Cambridge risk scores (AUC of
0.78 and 0.72, respectively). Interestingly, addition of
genetic information to phenotype-based risk models did
not improve prediction [20]. It is also possible that for
diabetic nephropathy the genotypic risk does not exceed the
risk contributed by conventional risk factors (e.g. BMI, age,
diabetes mellitus duration), which means that the predic-
tive value of risk variants for diabetic nephropathy
would be limited [21]. Although genetic prediction and
use of personalised medicine in diabetic nephropathy
remains a new undertaking, prediction is likely to improve
as additional disease variants are detected and replicated
[22].
Novel biological insights may lead to development of
new therapeutic targets, biomarkers and opportunities for
disease prevention. Hypothesis-free approaches, such as
GWAS, are most promising in this respect. At present, it
seems wise to focus on assessing the relevance of
previously detected genetic variants. As common SNPs
associated with diabetic nephropathy and detected by
GWAS may represent rare genetic variants with large
effects, sequencing the regions surrounding highly signif-
icant and replicated genomic regions to detect rare variants
appears to be reasonable. Follow-up in vitro and in vivo
studies could then assess the functional relevance of these
variants in diabetic nephropathy.
In summary, our meta-analysis identified 24 genetic
variants (in or near 16 different genes) associated with
advanced diabetic nephropathy. These genetic variants are
likely to represent true associations and further investiga-
tions to elucidate their functional relationship in diabetic
nephropathy should be pursued.
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